Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Background Obesity is a globally growing health problem, and its treatment has been challenging. The use of anti-obesity medications (AOMs) has been associated with severe adverse events (AEs). Several AOMs have been withdrawn from the market owing to documented AEs. Aim To describe, estimate and characterize the frequency of AEs attributable to the use of the AOMs, and investigate previously unreported potential AEs associated with AOMs. Method Using the US FDA Adverse Event Reporting System (FAERS) between January 2013 and June 2020, a retrospective, descriptive analysis was conducted to analyze all major reported AEs and outcomes including death, life-threatening, hospitalization, disability, and required intervention or congenital anomaly. The total numbers of AEs reports, cases, adverse reactions and outcomes were calculated for each medication. Results A total of 18,675 unique AEs reports associated with AOMs used for 15,143 patients. The mean age was 49.8 years [SD 1.83], while most patients were female adults (73.4%). The most frequently reported AEs were nausea and vomiting, followed by dizziness and headache, drug ineffectiveness, cardiovascular diseases, and kidney complications. There were 21,229 unique outcomes, including 1039 deaths (fatality ratio of 4.9% of all analyzed reports), 1613 (7.6%) life-threatening events, 7426 (35%) hospitalizations, and 1249 (5.9%) disability cases. Phentermine/topiramate fatal cases represent 6% of the overall medication's reported AEs. Cardiovascular AEs represented 31%, 23%, and 22% of phentermine, liraglutide, and phentermine/topiramate total AEs, respectively. Conclusion The analysis of FAERS database revealed numerous serious AEs associated with AOMs. These AEs can lead to serious cardiovascular and kidney complications. It is necessary to continue and systematically monitor safety of AOMs' to optimize patient anti-obesity therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
The Disease Burden Associated With Overweight and Obesity
Must, A. (1999) · JAMA · doi:10.1001/jama.282.16.1523 · Cited by 4,780
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Impact of Overweight on the Risk of Developing Common Chronic Diseases During a 10-Year Period
Field, A. E., Coakley, E. H., Must, A., Spadano, J. L., Laird, N., Dietz, W. H., Rimm, E., & Colditz, G. A. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1581 · Cited by 1,694
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Aune, D., Sen, A., Prasad, M., Norat, T., Janszky, I., Tonstad, S., Romundstad, P., & Vatten, L. J. (2016) · BMJ · doi:10.1136/bmj.i2156 · Cited by 953
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
Overweight and obesity: prevalence, consequences, and causes of a growing public health problem
Williams, E. P., Mesidor, M., Winters, K., Dubbert, P. M., & Wyatt, S. B. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0169-4 · Cited by 922
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Bariatric surgery. A systematic review and meta-analysis
Buchwald, H., Avidor, Y., & Braunwald, E. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.12.068 · Cited by 542
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471
Anti-obesity drugs: past, present and future
Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009621 · Cited by 430
LeBlanc, E. S., O'Connor, E., Whitlock, E. P., Patnode, C. D., & Kapka, T. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-7-201110040-00006 · Cited by 400
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Finer, N., James, W., Kopelman, P., Lean, M., & Williams, G. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801128 · Cited by 325
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808721 · Cited by 265
A comprehensive examination of health conditions associated with obesity in older adults
Patterson, R. E., Frank, L. L., Kristal, A. R., & White, E. (2004) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2004.08.001 · Cited by 244
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Lindquist, M., St??hl, M., Bate, A., Edwards, I. R., & Meyboom, R. H. B. (2000) · Drug Safety · doi:10.2165/00002018-200023060-00004 · Cited by 230
Anti-obesity drugs: a review about their effects and their safety
Derosa, G., & Maffioli, P. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.675326 · Cited by 185
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184
FDA-Approved Anti-Obesity Drugs in the United States
Daneschvar, H. L., Aronson, M. D., & Smetana, G. W. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.009 · Cited by 170
Aagaard, L., Strandell, J., Melskens, L., Petersen, P. S. G., & Hansen, E. H. (2012) · Drug Safety · doi:10.1007/bf03262002 · Cited by 169
Neff, K., Olbers, T., & le Roux, C. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-8 · Cited by 144
Safety and tolerability of new-generation anti-obesity medications: a narrative review
Patel, D. K., & Stanford, F. C. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1435129 · Cited by 116
Updates on obesity pharmacotherapy
Velazquez, A., & Apovian, C. M. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13542 · Cited by 115
Global Patterns of Adverse Drug Reactions Over a Decade
Aagaard, L., Strandell, J., Melskens, L., et al. (2012) · Drug Safety · doi:10.2165/11631940-000000000-00000 · Cited by 110
Use of prescription antiobesity drugs in the United States.
Hampp, C., Kang, E. M., & Borders‐Hemphill, V. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1342 · Cited by 103
Hatahira, H., Abe, J., Hane, Y., Matsui, T., Sasaoka, S., Motooka, Y., Hasegawa, S., Fukuda, A., Naganuma, M., Ohmori, T., et al. (2017) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-017-0088-5 · Cited by 102
Johansson, K., Neovius, K., DeSantis, S. M., Rössner, S., & Neovius, M. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00581.x · Cited by 86
Correlates of body weight in the 1994 National Population Health Survey
Cairney, J., & Wade, T. J. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800632 · Cited by 84
New central targets for the treatment of obesity
Sargent, B. J., & Moore, N. A. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03550.x · Cited by 75
Aagaard, L., & Hansen, E. H. (2009) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-9-4 · Cited by 62
Pharmacotherapy for Obesity—Trends Using a Population Level National Database
Elangovan, A., Shah, R., & Smith, Z. L. (2021) · Obesity Surgery · doi:10.1007/s11695-020-04987-2 · Cited by 56
Teng, C., Walter, E. A., Gaspar, D. K. S., Obodozie-Ofoegbu, O. O., & Frei, C. R. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.34141 · Cited by 54
An unexpected result of obesity treatment: orlistat-related acute pancreatitis
Kose, M., Emet, S., Akpınar, T. S., Ilhan, M., Gok, A. F. K., Dadashov, M., & Tukek, T. (2015) · Case Reports in Gastroenterology · doi:10.1159/000430433 · Cited by 36
Kato, Y., Umetsu, R., Abe, J., Ueda, N., Nakayama, Y., Kinosada, Y., & Nakamura, M. (2015) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-015-0015-6 · Cited by 34
Aagaard, L., Hallgreen, C. E., & Hansen, E. H. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.135 · Cited by 15
Lorcaserin Departs, Leaving More Questions than Answers
Kumar, R. B., & Ryan, D. H. (2020) · Obesity · doi:10.1002/oby.22789 · Cited by 13
Cited by
Tobaiqy, M., & Elkout, H. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01694-7 · Cited by 88
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Ariaee, A., Wardill, H. R., Wignall, A. D., Prestidge, C. A., & Joyce, P. M. (2024) · Foods · doi:10.3390/foods13071039 · Cited by 33
Anti-obesity pharmacotherapy in adults with chronic kidney disease
Taber-Hight, E., Gilmore, A. C., & Friedman, A. N. (2023) · Kidney International · doi:10.1016/j.kint.2023.10.014 · Cited by 22
Yang, Q., Wang, J., Wang, M.-H., Zhang, S., & He, Q. (2024) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-024-00789-9 · Cited by 20
Metadata
- Authors
- Alsuhibani, A., Alrasheed, M., Gari, M., Hincapie, A. L., & Guo, J. J.
- Affiliations
- Qassim University (SA)
- King Saud University (SA)
- University of Cincinnati Medical Center (US)
- Corresponding author
- Alsuhibani, Abdulrahman
- Venue
- International Journal of Clinical Pharmacy
- Published
- 2021-09-26
- Volume
- 44
- Issue
- 1
- Pages
- 172-179
- ISSN
- 2210-7703 (ISSN-L)
- 2210-7711
- OpenAlex
- W3175042504
- Cited by
- 19
- References
- 45
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 4 · 2023: 2 · 2021: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- International Journal of Clinical Pharmacy (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- anti-obesity drugs, adverse drug reactions, drug safety, phentermine/topiramate, liraglutide, cardiovascular adverse events, renal complications, drug-induced death, drug withdrawal, adverse event reporting
- MeSH terms
- Adult, Female, Humans, Middle Aged, Obesity, Retrospective Studies, United States, United States Food and Drug Administration, Databases, Factual, Adverse Drug Reaction Reporting Systems, Anti-Obesity Agents, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.